MHRA Approves New Prophylactic for Rare Swelling Disorder Edited by Zeel Mehta Medscape UK May 11, 2026

https://www.medscape.com/viewarticle/mhra-approves-new-prophylactic-rare-swelling-disorder-2026a1000f05 The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Dawnzera (donidalorsen, Otsuka Pharmaceutical Netherlands B.V.) for the prevention of swelling attacks in patients aged 12 years or older with hereditary angioedema. The approval was granted through the International Recognition Procedure.